|
|
Volumn 2, Issue 3, 2001, Pages 193-194
|
|
Neoadjuvant androgen ablation before radical prostatectomy reduces positive margin rate, but has no effect on 36-month post-treatment biochemical failure.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANDROGEN;
ADJUVANT THERAPY;
ARTICLE;
CATHETER ABLATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
HUMAN;
MALE;
METABOLISM;
OUTCOME ASSESSMENT;
PROSTATE TUMOR;
PROSTATECTOMY;
RANDOMIZED CONTROLLED TRIAL;
TIME;
ANDROGENS;
CATHETER ABLATION;
HUMANS;
MALE;
NEOADJUVANT THERAPY;
OUTCOME ASSESSMENT (HEALTH CARE);
PROSTATECTOMY;
PROSTATIC NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS;
TIME FACTORS;
|
|
EID: 0035372345
PISSN: 15272737
EISSN: None
Source Type: Journal
DOI: 10.1007/s11934-001-0077-x Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
